Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter   Stable first six months: consolidated revenue and adjusted EBITDA in line with expectations. Operational strength: EBITDA up 3.7% in Q2 2025 versus prior-year quarter. Branded pharmaceuticals remain growth driver with strong EB [ … ]

Dermapharm Holding SE remains on projected growth trajectory in Q2 2025    Board of Management confirms full-year guidance for 2025, continues to expect consolidated revenue of EUR 1,160–1,200 million and increase in adjusted EBITDA to EUR 322–332 million Organic growth in branded pharmaceuticals largely offsets expected decline from realignment  [ … ]

Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.90 per share   2025 outlook confirmed Board of Management and Supervisory Board actions ratified with large majority Shareholders resolve dividend payment of EUR 0.90 per share   Grünwald, 26 June 2025 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing [ … ]

Dermapharm Holding SE performs in line with projections in Q1 2025, confirms full-year guidance   Strong organic growth in high-margin "Branded pharmaceuticals" and revenue growth in "Parallel import business" segment more than offset slight decline in revenue from "Other healthcare products" segment Consolidated revenue increases by 1.2% year o [ … ]

Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance   Consolidated revenue up 4.0% to EUR 1,180.8 million (Unadjusted) consolidated EBITDA increases by 10.2% to EUR 308.9 million, unadjusted EBITDA margin at 26.2% (Adjusted) EBITDA of EUR 315.6 million produces adjusted EBITDA margin of 26.7%; adjustments d [ … ]

Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA   Consolidated revenue up 4.0% to EUR 1,180.8 million, driven by strong organic growth in the "Branded pharmaceuticals" segment Above-average increase in unadjusted consolidated EBITDA by 10.2% to EUR 308.9 million, unadjusted EBITDA margi [ … ]